newsfilter
← Latest News
GlobeNewswire·

Century Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates

Completed pre-IND meeting with the FDA for CNTY-813, an iPSC-derived islet replacement therapy with functional cure potential in type 1 diabetes (T1D); IND submission on track for 4Q 2026CNTY-813 preclinical data from